drugset
drugset / Trial / NCT04837001

Evaluation in STEMI Patients Using FDY-5301

NCT04837001 ↗

Phase 3 Completed 2351 enrolled Faraday Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To assess the effect of FDY-5301 on cardiovascular mortality and acute heart failure events in subjects with an anterior STEMI undergoing pPCI.

Timeline

Start
2022-05-02
Primary completion
2025-09-03
Completion
2025-09-03

Drugs

EvaluationDrugModalityDoseRoute
Subject FDY-5301 Small molecule — Intravenous

Indications

ST-elevation myocardial infarction